• About Us
    • About AMDAPP
    • Board of Directors
    • Executive Committee & Advisors
    • Community Partners
    • Corporate Roundtable
    • Founder’s Circle
    • Newsletter
  • Certification
  • Onboarding
  • Discussion
  • Events
  • Membership
  • Login
  • About Us
    • About AMDAPP
    • Board of Directors
    • Executive Committee & Advisors
    • Community Partners
    • Corporate Roundtable
    • Founder’s Circle
    • Newsletter
  • Certification
  • Onboarding
  • Discussion
  • Events
  • Membership
  • Login
  • About Us
    • About AMDAPP
    • Board of Directors
    • Executive Committee & Advisors
    • Community Partners
    • Corporate Roundtable
    • Founder’s Circle
    • Newsletter
  • Certification
  • Onboarding
  • Discussion
  • Events
  • Membership
  • Login
  • About Us
    • About AMDAPP
    • Board of Directors
    • Executive Committee & Advisors
    • Community Partners
    • Corporate Roundtable
    • Founder’s Circle
    • Newsletter
  • Certification
  • Onboarding
  • Discussion
  • Events
  • Membership
  • Login
Donate

Category: Pearls and Tx Updates

Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage Background…

tasha
Tasha April 10, 2025
0 Comments

Effect of Opicapone and Entacapone on Early Morning-OFF Pattern in Parkinson’s Disease Patients with Motor Fluctuations

Effect of Opicapone and Entacapone on Early Morning-OFF Pattern in Parkinson’s Disease Patients with Motor Fluctuations Objective: To evaluate the effect of opicapone (OPC) 50 mg…

tasha
Tasha April 10, 2025
0 Comments

Impact of IPX203 (CREXONT®) on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

Impact of IPX203 (CREXONT®) on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data Objective: To evaluate “On” upon awakening in Parkinson’s disease patients…

tasha
Tasha April 10, 2025
0 Comments

Extended-release carbidopa-levodopa: How is CREXONT® different from RYTARY®?

Extended-release carbidopa-levodopa: How is CREXONT® different from RYTARY®? Objective: To compare two oral extended-release (ER) carbidopa-levodopa (CD-LD) formulations, CREXONT®  and RYTARY®

tasha
Tasha April 10, 2025
0 Comments

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease Question  Can extended-release carbidopa-levodopa (IPX203) improve symptomatic control in patients with Parkinson disease…

tasha
Tasha April 10, 2025
0 Comments

Sustained Treatment Response and Global ImprovementsWith Long-term Valbenazine in Patients

Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients Purpose/Background: Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post…

zinne2
Erin Zinn December 10, 2024
0 Comments

An Evidence‐Based Update on Anticholinergic Use for Drug‐InducedMovement Disorders

An Evidence‐Based Update on Anticholinergic Use for Drug‐InducedMovement Disorders Drug-induced movement disorders (DIMDs) are associated with use of dopamine receptor blocking agents (DRBAs), including antipsychotics.…

zinne2
Erin Zinn December 10, 2024
0 Comments

VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia

VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia Psychiatric nurses are at the forefront of optimizing psychiatric care, including educating patientsand caregivers on the risks…

zinne2
Erin Zinn December 10, 2024
0 Comments

Parkinsonism Differential Diagnosis

Parkinsonism Differential Diagnosis Arriving at a differential diagnosis for Parkinsonism can be challenging. Below is a reference sheet that may help  in your determination. Following…

admin
Bee Roos March 19, 2024

INforMD – Phase 3 Foslevodopa-Foscarbidopa – AbbVie

INforMD – Phase 3 Foslevodopa-Fascarbidopa – AbbVie This article provides a comprehensive report on the Phase 3 trials of subcutaneous foslevodopa-fascarbidopa currently under development through…

admin
Bee Roos October 25, 2023
  • About Us
  • Support Us
  • Join
  • Privacy Policy
  • About Us
  • Support Us
  • Join
  • Privacy Policy

Contact Us: hello@amdapp.org

A nonprofit 501c3 membership organization   EIN 92-0662557

 

© 2024 AMDAPP 

Add us to your inbox!

We hate spam, and we respect your privacy!

 

  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates

Add us to your inbox!

We hate spam, and we respect your privacy!

  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
Donate
Facebook Twitter Instagram
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
Donate
Facebook Twitter Instagram
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates
  • Alternative Therapies
  • Biomarkers and Genetics
  • Diversity, Equity, and Inclusion
  • INforMD
  • Pearls and Tx Updates